Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Divestments (2022 - 2023)

Marker Therapeutics (MRKR) has disclosed Divestments for 2 consecutive years, with $18.8 million as the latest value for Q2 2023.

  • Quarterly Divestments changed N/A to $18.8 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $18.7 million through Dec 2023, changed N/A year-over-year, with the annual reading at $18.7 million for FY2023, 477.42% up from the prior year.
  • Divestments for Q2 2023 was $18.8 million at Marker Therapeutics, up from -$112608.0 in the prior quarter.
  • The five-year high for Divestments was $18.8 million in Q2 2023, with the low at -$127342.0 in Q4 2022.